FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2550930186> ?p ?o ?g. }

• W2550930186 abstract "Abstract Abstract 2652 Introduction Despite improvements in cure rates for patients with diffuse large B-cell lymphoma (DLBCL), up to 40% relapse after achieving initial remission, mostly within 18 months from treatment. There is no consensus as to role, or most appropriate form of post-remission surveillance. Our aim was to explore the role of Positron Emission Tomography combined with computer tomography (PET-CT) scanning in the follow up of patients with diffuse large B-cell lymphoma (DLBCL) achieving complete metabolic response (CMR) after primary therapy, identify patterns of relapse and define a risk-adapted strategy. Results We included 116 patients with de novo DLBCL treated at our centre between 2002 and 2009 with a negative post-treatment PET-CT, and at least one surveillance PET-CT scan. International Prognostic Index (IPI) was <3 in 77 (66%) and ≥3 in 37 (32%) patients. With a median follow up of 53 months (range 8–133), 456 surveillance scans were performed (range 1–10 per patient). 13 patients (11%) relapsed, with an actuarial 5 year relapse free survival of 86%. Two-thirds of relapses occurred in the first 18 months following completion of treatment. In seven cases (54%), the relapse was suspected based on symptoms and in six (46%) the relapse was subclinical and detected with PET. There was no difference in survival (P=0.76) or second line IPI (P=1.00) between the groups, as the number of relapses was small. PET-CT had very high sensitivity (100%), specificity (98%) and negative predictive value (NPV, 100%) with positive predictive value (PPV) 56% in the cohort of patients with a low IPI (<3) compared with 80% if the IPI was ≥3. Across the entire cohort, the average number of patients in remission needed to scan to detect one subclinical relapse within the first 18 months was 42. However, for those with an IPI ≥3 the number needed to scan to detect one subclinical relapse was 22. Surveillance PET-CT had a very low yield after 18 months had elapsed from the conclusion of primary therapy (1 true positive among 170 scans). Interim response PET-CT was performed in 81 (70%) patients; achieving CMR was not a predictor of time to relapse (P=0.65) or having a positive surveillance scan, irrespective of IPI (P=1.00). Second malignancies were detected by PET-CT in eight patients (7%). Conclusion The achievement of CMR at the completion of primary therapy identifies a group of patients with favourable outlook and a low risk of relapse. Surveillance PET-CT scanning within this select cohort has high sensitivity, specificity and NPV and despite the low number of relapses retains a high PPV, particularly in patients with IPI≥3. Surveillance PET-CT is useful in the first 18 months following completion of primary therapy in patients in whom IPI at diagnosis is ≥3. We feel that such a strategy would be appropriate to evaluate in a prospective comparative trial. Disclosures: No relevant conflicts of interest to declare." @default.
• W2550930186 created "2016-11-30" @default.
• W2550930186 creator A5001557317 @default.
• W2550930186 creator A5007604802 @default.
• W2550930186 creator A5021020612 @default.
• W2550930186 creator A5023868942 @default.
• W2550930186 creator A5028575111 @default.
• W2550930186 creator A5034869949 @default.
• W2550930186 creator A5038360792 @default.
• W2550930186 creator A5042336840 @default.
• W2550930186 creator A5053768191 @default.
• W2550930186 creator A5059822664 @default.
• W2550930186 creator A5063276705 @default.
• W2550930186 creator A5071712855 @default.
• W2550930186 creator A5078346197 @default.
• W2550930186 creator A5081326206 @default.
• W2550930186 creator A5085013906 @default.
• W2550930186 date "2012-11-16" @default.
• W2550930186 modified "2023-09-27" @default.
• W2550930186 title "Surveillance PET-CT Scanning Is Useful in the First 18 Months Following Completion of Therapy for Patients with Diffuse Large B-Cell Lymphoma with IPI≥3." @default.
• W2550930186 doi "https://doi.org/10.1182/blood.v120.21.2652.2652" @default.
• W2550930186 hasPublicationYear "2012" @default.
• W2550930186 type Work @default.
• W2550930186 sameAs 2550930186 @default.
• W2550930186 citedByCount "0" @default.
• W2550930186 crossrefType "journal-article" @default.
• W2550930186 hasAuthorship W2550930186A5001557317 @default.
• W2550930186 hasAuthorship W2550930186A5007604802 @default.
• W2550930186 hasAuthorship W2550930186A5021020612 @default.
• W2550930186 hasAuthorship W2550930186A5023868942 @default.
• W2550930186 hasAuthorship W2550930186A5028575111 @default.
• W2550930186 hasAuthorship W2550930186A5034869949 @default.
• W2550930186 hasAuthorship W2550930186A5038360792 @default.
• W2550930186 hasAuthorship W2550930186A5042336840 @default.
• W2550930186 hasAuthorship W2550930186A5053768191 @default.
• W2550930186 hasAuthorship W2550930186A5059822664 @default.
• W2550930186 hasAuthorship W2550930186A5063276705 @default.
• W2550930186 hasAuthorship W2550930186A5071712855 @default.
• W2550930186 hasAuthorship W2550930186A5078346197 @default.
• W2550930186 hasAuthorship W2550930186A5081326206 @default.
• W2550930186 hasAuthorship W2550930186A5085013906 @default.
• W2550930186 hasConcept C126322002 @default.
• W2550930186 hasConcept C126838900 @default.
• W2550930186 hasConcept C2775842073 @default.
• W2550930186 hasConcept C2778476033 @default.
• W2550930186 hasConcept C2778559949 @default.
• W2550930186 hasConcept C2779338263 @default.
• W2550930186 hasConcept C2989005 @default.
• W2550930186 hasConcept C71924100 @default.
• W2550930186 hasConcept C72563966 @default.
• W2550930186 hasConceptScore W2550930186C126322002 @default.
• W2550930186 hasConceptScore W2550930186C126838900 @default.
• W2550930186 hasConceptScore W2550930186C2775842073 @default.
• W2550930186 hasConceptScore W2550930186C2778476033 @default.
• W2550930186 hasConceptScore W2550930186C2778559949 @default.
• W2550930186 hasConceptScore W2550930186C2779338263 @default.
• W2550930186 hasConceptScore W2550930186C2989005 @default.
• W2550930186 hasConceptScore W2550930186C71924100 @default.
• W2550930186 hasConceptScore W2550930186C72563966 @default.
• W2550930186 hasLocation W25509301861 @default.
• W2550930186 hasOpenAccess W2550930186 @default.
• W2550930186 hasPrimaryLocation W25509301861 @default.
• W2550930186 hasRelatedWork W2008433888 @default.
• W2550930186 hasRelatedWork W2023406498 @default.
• W2550930186 hasRelatedWork W2028278523 @default.
• W2550930186 hasRelatedWork W2199828942 @default.
• W2550930186 hasRelatedWork W2344891174 @default.
• W2550930186 hasRelatedWork W2412229555 @default.
• W2550930186 hasRelatedWork W2460608036 @default.
• W2550930186 hasRelatedWork W2552834691 @default.
• W2550930186 hasRelatedWork W2558697897 @default.
• W2550930186 hasRelatedWork W2559559559 @default.
• W2550930186 hasRelatedWork W2571016527 @default.
• W2550930186 hasRelatedWork W2582393469 @default.
• W2550930186 hasRelatedWork W2587775779 @default.
• W2550930186 hasRelatedWork W2789178794 @default.
• W2550930186 hasRelatedWork W2978428646 @default.
• W2550930186 hasRelatedWork W2978502618 @default.
• W2550930186 hasRelatedWork W2995838903 @default.
• W2550930186 hasRelatedWork W3048408104 @default.
• W2550930186 hasRelatedWork W1649161558 @default.
• W2550930186 hasRelatedWork W2783383040 @default.
• W2550930186 isParatext "false" @default.
• W2550930186 isRetracted "false" @default.
• W2550930186 magId "2550930186" @default.
• W2550930186 workType "article" @default.